1,722,007 research outputs found
"Molecular profiling and ways towards personalized medicine in advanced differentiated thyroid cancer".
No full text[Intravenous immunoglobulins. General features and the main clinical applications].
No full textIntravenous immunoglobulins are stable pooled human IgG preparations for therapeutic use. Intravenous immunoglobulins are used for replacement therapy for patients with primary or secondary antibody immunodeficiency, and they are also beneficial in the prevention and treatment of certain viral infections, such as cytomegalovirus pneumonia and Varicella-Zoster; they may also have a synergistic effect with antibiotics in some bacterial diseases. Intravenous immunoglobulins have also been used successfully in the treatment of idiopathic thrombocytopenic purpura, Kawasaki disease and other autoimmune diseases such as Graves ophthalmopathy. Disadvantages of intravenous immunoglobulins include some frequent (10%) but usually not serious side effects and high cost; rarely has transmission of viral infections been reported
Generative AI in scientific publishing: disruptive or destructive?
No full textArtificial intelligence (AI) has the potential to revolutionize scientific publishing. The influence of AI could be disruptive or destructive and its influence remains to be seen, but balance between the convenience and accessibility offered by AI-driven tools and the essential skills of deep scientific inquiry and communication needs to be found
Inositol(s) in thyroid function, growth and autoimmunity
No full textMyo-inositol and phosphatidylinositol(s) play a pivotal function in many metabolic pathways that, if impaired, impact unfavorably on human health. This review analyzes several experimental and clinical investigations regarding the involvement of this class of molecules in physiological and pathological situations, with a major focus on thyroid. Central issues are the relationship between phosphatidylinositol and thyrotropin (TSH) signaling on one hand, and phosphatydylinositol and autoimmunity on the other hand. Other issues are the consequences of malfunction of some receptors, such as those ones for TSH (TSHR), insulin (IR) and insulin-like growth factor-1 (IGF-1R), or the connection between serum TSH concentrations and insulin resistance. Also covered are insulin resistance, metabolic syndrome and their allied disorders (diabetes, polycystic ovary syndrome [PCOS]), autoimmunity and certain malignancies, with their reciprocal links. Myoinositol has promising therapeutic potential. Appreciation of the inositol pathways involved in certain disorders, as mentioned in this review, may stimulate researchers to envisage additional therapeutic applications
New therapies, markers and therapeutic targets in HCV chronic infection, and HCV extrahepatic manifestations
Full text linkMore than 180 millions of subjects in the world are infected by Hepatitis C Virus (HCV), and about 20% of them with HCV chronic infection progress to cirrhosis. Furthermore, numerous HCV extrahepatic manifestations have been reported in up to 74% of patients, as mixed cryoglobulinemia, lymphomas, rheumatic disorders, autoimmune thyroiditis, hypothyroidism, papillary thyroid cancer, and type 2 diabetes. Advances in understanding the HCV life cycle, and the inflammatory processes (involving a complex network of cytokines and chemokines) associated with HCV chronic infection, have led to substantial advancements in therapy. The combination of ribavirin and PEGylated interferon-gamma was the standard of therapy for HCV chronically infected patients in the last decades. However, interferon has limited effectiveness and is associated with severe adverse effects. Recently, direct-acting antivirals (DAAs) that act as inhibitors of N5SA, or polymerase, or protease have been shown to result in shorter duration of therapy, better efficacy and tolerance, with respect to ribavirin and PEGylated interferon-gamma. Circulating CXCL10 levels, and the interleukin(IL)-28B gene polymorphisms, are associated with the success of the therapy both with DAAs or ribavirin and PEGylated interferon-alpha. New DAAs targeting the HCV at various molecular levels have been developed to eradicate HCV. Moving to interferon-free therapies should offer new treatments for resistant HCV genotypes, and for ineligible patients or patients failing to respond to prior therapies. Many efforts have been made to understand the factors that are involved with clearance of HCV to personalize the therapy for each patient, with the aim to reduce side effects, increasing the sustained virologic response rate, and to prevent the progression of the disease
Re: Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial
No full textN.A
- …
